DaVita Inc. (NYSE:DVA) Receives $164.50 Average PT from Analysts

DaVita Inc. (NYSE:DVA - Get Free Report) has been given an average rating of "Hold" by the six analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $164.50.

DVA has been the subject of several analyst reports. Truist Financial lowered their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. Cowen restated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Finally, Barclays raised their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th.

Institutional Trading of DaVita

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP increased its holdings in DaVita by 9.1% during the 4th quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock worth $405,000 after purchasing an additional 227 shares during the period. Hussman Strategic Advisors Inc. grew its position in shares of DaVita by 200.0% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company's stock worth $3,769,000 after buying an additional 16,800 shares in the last quarter. Caprock Group LLC purchased a new position in shares of DaVita during the fourth quarter valued at $200,000. Yousif Capital Management LLC increased its stake in shares of DaVita by 22.1% during the fourth quarter. Yousif Capital Management LLC now owns 10,362 shares of the company's stock valued at $1,550,000 after buying an additional 1,877 shares during the period. Finally, Convergence Investment Partners LLC raised its holdings in shares of DaVita by 33.2% in the fourth quarter. Convergence Investment Partners LLC now owns 11,389 shares of the company's stock valued at $1,703,000 after acquiring an additional 2,836 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

DaVita Price Performance

Shares of DaVita stock traded down $0.24 during trading hours on Thursday, reaching $136.09. The company's stock had a trading volume of 1,163,940 shares, compared to its average volume of 822,874. The firm has a 50 day moving average price of $144.09 and a 200-day moving average price of $152.85. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The stock has a market cap of $10.27 billion, a P/E ratio of 12.67, a P/E/G ratio of 1.07 and a beta of 1.14. DaVita has a one year low of $131.76 and a one year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. The business had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The company's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the company earned $2.26 EPS. On average, analysts predict that DaVita will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.